Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CFDA Accepts CStone's IND Submission for PD-L1 Candidate

publication date: Oct 19, 2016
CStone Pharma, a young Shanghai-Suzhou startup, reported that its application for clinical trials of a recombinant PD-L1 antibody was accepted for review by the CFDA. According to CStone, the candidate (WBP3155) is China's first innovative, fully humanized, full-length original format Immunoglobulin G (IgG) mAb candidate. WBP3155 was produced by the OMT platform, which suggests a connection with WuXi AppTec. WuXi in-licensed rights to the OMT platform for mAb discovery. In July, CStone raised $150 million in an A round from three China investors including WuXi Healthcare Ventures. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital